Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat - The effect of AT1-R blocker on the hepatic fibrosis


TUNCER İ. , özbek H., Uğraş S., Bayram İ.

EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, vol.55, pp.159-166, 2003 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Article
  • Volume: 55
  • Publication Date: 2003
  • Doi Number: 10.1016/s0940-2993(04)70155-4
  • Title of Journal : EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
  • Page Numbers: pp.159-166

Abstract

Background/Aim: Angiotensin converting enzyme (ACE) and angiotensin II (AT-II) have been suggested to play an important role in liver fibrogenesis. There is a significant relationship between inheritance of hightened expression of transforming growth factor beta1 (TGF-beta1) and AT-II and the development of progressive hepatic fibrosis. The purpose of this study was to investigate the effects of captopril. an ACE inhibitor and candesartan cilexetil, an AT-II type I receptor (AT1-R) blocker, on liver fibrosis induced in rats by carbon tetrachloride (CCl4) administration.